Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 337

1.

Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII.

Filsoufi F, Castillo JG, Rahmanian PB, Scurlock C, Fischer G, Adams DH.

Ann Thorac Surg. 2006 Nov;82(5):1779-83.

PMID:
17062247
2.

The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.

Pychyńska-Pokorska M, Moll JJ, Krajewski W, Jarosik P.

Pediatr Crit Care Med. 2004 May;5(3):246-50.

PMID:
15115562
3.

Recombinant activated factor VII for refractory bleeding after cardiac surgery--a retrospective analysis of safety and efficacy.

von Heymann C, Redlich U, Jain U, Kastrup M, Schroeder T, Sander M, Grosse J, Ziemer S, Koscielny J, Konertz WF, Wernecke KD, Spies C.

Crit Care Med. 2005 Oct;33(10):2241-6.

PMID:
16215377
4.

Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis.

Gelsomino S, Lorusso R, Romagnoli S, Bevilacqua S, De Cicco G, Billè G, Stefàno P, Gensini GF.

Eur J Cardiothorac Surg. 2008 Jan;33(1):64-71. Epub 2007 Nov 8.

PMID:
17996457
5.

[The use of recombinant activated factor VII for blood loss after cardiovascular surgery].

Gong ZY, Gao CQ, Xiao CS, Li BJ, Ma XH, Zhang CM.

Zhonghua Wai Ke Za Zhi. 2008 Oct 1;46(19):1497-501. Chinese.

PMID:
19094631
6.

Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications.

Bhaskar B, Zeigenfuss M, Choudhary J, Fraser JF.

Transfusion. 2013 Apr;53(4):798-804. doi: 10.1111/j.1537-2995.2012.03801.x. Epub 2012 Jul 31.

PMID:
22845023
7.

Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery.

Raivio P, Suojaranta-Ylinen R, Kuitunen AH.

Ann Thorac Surg. 2005 Jul;80(1):66-71.

PMID:
15975342
8.

Role of factor VII in correcting dilutional coagulopathy and reducing re-operations for bleeding following non-traumatic major gastrointestinal and abdominal surgery.

Tsai TC, Rosing JH, Norton JA.

J Gastrointest Surg. 2010 Aug;14(8):1311-8. doi: 10.1007/s11605-010-1227-6. Epub 2010 Jun 2.

9.

Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.

Razon Y, Erez E, Vidne B, Birk E, Katz J, Tamari H, Dagan O.

Paediatr Anaesth. 2005 Mar;15(3):235-40.

PMID:
15725322
10.

Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.

Dunkley S, Phillips L, McCall P, Brereton J, Lindeman R, Jankelowitz G, Cameron P.

Ann Thorac Surg. 2008 Mar;85(3):836-44. doi: 10.1016/j.athoracsur.2007.06.076.

PMID:
18291152
11.

Safe use of recombinant activated factor VIIa for recalcitrant postoperative haemorrhage in cardiac surgery.

Tatoulis J, Theodore S, Meswani M, Wynne R, Hon-Yap C, Powar N.

Interact Cardiovasc Thorac Surg. 2009 Sep;9(3):459-62. doi: 10.1510/icvts.2009.204735. Epub 2009 Jun 18.

PMID:
19542087
12.

Is recombinant activated factor VII effective in the treatment of excessive bleeding after paediatric cardiac surgery?

Okonta KE, Edwin F, Falase B.

Interact Cardiovasc Thorac Surg. 2012 Oct;15(4):690-4. Epub 2012 Jul 18. Review.

13.

Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.

Mitsiakos G, Papaioannou G, Giougi E, Karagianni P, Garipidou V, Nikolaidis N.

J Pediatr Hematol Oncol. 2007 Mar;29(3):145-50.

PMID:
17356391
14.

Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes.

Uber WE, Toole JM, Stroud MR, Haney JS, Lazarchick J, Crawford FA Jr, Ikonomidis JS.

J Thorac Cardiovasc Surg. 2011 Jun;141(6):1469-77.e2. doi: 10.1016/j.jtcvs.2011.02.033. Epub 2011 Mar 31.

15.

Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.

Pychyńska-Pokorska M, Pągowska-Klimek I, Krajewski W, Moll JJ.

J Cardiothorac Vasc Anesth. 2011 Dec;25(6):987-94. doi: 10.1053/j.jvca.2011.05.012. Epub 2011 Aug 11.

PMID:
21835642
16.

Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery.

McCall P, Story DA, Karalapillai D.

Can J Anaesth. 2006 Sep;53(9):926-33. Erratum in: Can J Anaesth. 2006 Dec;53(12):1271. Karapillai, Darshi [corrected to Karalapillai, Darshi].

PMID:
16960271
17.
18.

Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.

Mayo A, Misgav M, Kluger Y, Geenberg R, Pauzner D, Klausner J, Ben-Tal O.

Vox Sang. 2004 Jul;87(1):34-40. Review.

PMID:
15260820
19.

[Efficacy of recombinant activated factor VII for massive bleeding after cardiac surgery: experience with 32 patients].

Millán C, Quintana B, Rodríguez A, Iglesias M, Barranco M, Navia J.

Rev Esp Anestesiol Reanim. 2009 Oct;56(8):485-92. Spanish.

PMID:
19994617
20.

The clinical and laboratory response to recombinant factor VIIA in trauma and surgical patients with acquired coagulopathy.

McMullin NR, Kauvar DS, Currier HM, Baskin TW, Pusateri AE, Holcomb JB.

Curr Surg. 2006 Jul-Aug;63(4):246-51.

PMID:
16843774

Supplemental Content

Support Center